It’s time for an important update on the KRAS landscape and emerging opportunities in this niche.
I’ve mentioned this a few times, but the real kicker is going to come from rational combinations in different settings. Those companies who figure these out will emerge a stronger player than their competitors who focus on monotherapy.
With this idea in mind it behooves us to be alert and aware of what’s going on in the broader landscape beyond selective KRAS inhibitors against certain mutants.
Here we discuss the latest findings from two such targets, each quite different and yet both could have important roles to play going forward…